Home
»
Press Room
»
Epithelioma Treatment Market To Reach $9.73Bn By 2030

Epithelioma Treatment Market To Reach $9.73 Billion By 2030

January 2025 | Report Format: Electronic (PDF)

Epithelioma Treatment Market Growth & Trends

The global epithelioma treatment market size is expected to reach USD 9.73 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of skin cancers, notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a major driver of market expansion. According to the American Cancer Society, the U.S. is expected to see approximately 100,640 new cases of melanoma in 2024, with around 59,170 in men and 41,470 in women. Additionally, melanoma is anticipated to cause about 8,290 deaths, including 5,430 men and 2,860 women. This escalating prevalence underscores the increasing demand for advanced treatments and contributes significantly to the market’s growth.

Advancements in medical technology also play a crucial role. The development of innovative therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab) and targeted therapies (e.g., vismodegib for BCC), has revolutionized treatment options, offering new hope for patients and expanding market opportunities. These advancements are further supported by positive clinical trial results and FDA approvals, which underscore the efficacy and safety of these treatments.

Regulatory bodies and government initiatives are also pivotal in shaping the market. In the U.S., the FDA's accelerated approval process for promising treatments facilitates faster access to new therapies. Additionally, initiatives like the European Medicines Agency (EMA) provide crucial support in developing and approving new drugs in Europe. Government funding for cancer research and public awareness campaigns are enhancing early detection and treatment, further driving market growth.

key Request a free sample copy or view report summary: Epithelioma Treatment Market Report

Epithelioma Treatment Market Report Highlights

Based on type, basal cell epithelioma dominated the market and accounted for a share of 61.0% in 2024. BCC, a type of basal cell epithelioma, is the most common form of skin cancer globally.
Based on drug class, the hedgehog pathway inhibitors segment secured the largest revenue share of over 41.2% in 2024. This prominence is attributed to the efficacy of these inhibitors in treating BCC, the increasing incidence of skin cancers, and significant recent advancements in drug development.
Based on distribution channel, The hospital pharmacies segment led the market in 2024, capturing a substantial revenue share of over 51.8%.
North America epithelioma treatment market dominated the global market with a revenue share of 37.5% in 2024, largely fueled by the high incidence of skin cancers and a well-established healthcare infrastructure.